7+ hour, 10+ min ago  (489+ words) In the life sciences industry, we measure outcomes as value: revenue, pipeline velocity, time to market, shareholder return. Often, we ask for short-term Return on Investment (ROI). But here's the uncomfortable question: when it comes to patient engagement, are we…...

5+ hour, 58+ min ago  (299+ words) A broad mix of senior leadership and scientific and commercial appointments shaped last month's pharma and biotech hiring activity, with companies strengthening capabilities across AI, business development, R&D, and more. Read on for the highlights from March. Commit Biologics…...

6+ hour, 12+ min ago  (712+ words) For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next. For many life sciences start-ups, bringing on a GC early can be a strategic advantage. An experienced GC…...

1+ day, 10+ hour ago  (478+ words) Chinese start-up Syneron Bio has closed a $150 million second round, just four months after its $100 million first round, as it strives to carve out a position in the competitive macrocyclic peptide category. The Beijing biotech has been set up to…...

2+ day, 8+ hour ago  (674+ words) Cell and gene therapy (CGT) has had a tough few years, with questions over cost, scalability and manufacturing making investors think twice about plunging in. But the depth and breadth of innovation taking place in the sector is staggering. Last…...

3+ day, 7+ hour ago  (441+ words) Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio, a specialist in applying AI to drug discovery that was set up last year, but until now has been operating under the radar. San…...

3+ day, 9+ hour ago  (491+ words) A bispecific antibody that Sanofi thinks could be a future star of its immunology and inflammation business has hit the mark in two midstage trials in respiratory indications, but fallen short in a third in atopic dermatitis. On the plus…...

4+ day, 11+ hour ago  (610+ words) Small and mid-sized biotherapeutic companies are the primary engine of the biopharma industry, driving significant medical innovation. Large pharmaceutical companies increasingly view these smaller firms as their innovation laboratory. However, while these nimble firms benefit from being faster and more…...

1+ week, 1+ day ago  (922+ words) In a recent webinar sponsored by Lumanity " Using AI-driven synthetic personas to take your insights further " Damian Eade, Technology Transformation Officer, Insight, at Lumanity and St'phane Lebrat, Global Insights and Analytics Director at Takeda, discussed how, as AI continues to…...

1+ week, 1+ day ago  (508+ words) Korsana Biosciences only emerged onto the scene a few weeks ago, but is already planning to go public to raise funds for its Alzheimer's disease candidate. The start-up will achieve that through a reverse merger with Cyclerion Therapeutics, a Nasdaq-listed…...